Výsledky vyhledávání - "Mark W Russo"

Akademický článek

Impact of the Corona Virus Disease 2019 Pandemic on Hepatology Practice and Provider Burnout

Autor: Mark W. Russo, Ryan Kwok, Marina Serper, Nneka Ufere, Bilal Hameed, Jaime Chu, Elizabeth Goacher, John Lingerfelt, Norah Terrault, K. Rajender Reddy

Publikováno v: Hepatology Communications, Vol 6, Iss 5, Pp 1236-1247 (2022)

The corona virus disease 2019 (COVID‐19) pandemic has had a wide‐ranging impact on the clinical practice of medicine and emotional well‐being of providers. Our aim was to determine the impact of the COVID‐19 pandemic on practice and burnout a

Externí odkaz: https://doaj.org/article/161d240aa76e45ae8e59324b4605cd07

Zobrazit plný text záznamu

Prognostic modeling in biliary diseases

Autor: Camelia Ciobanu, Mark W. Russo

Publikováno v: Current Opinion in Gastroenterology. 39:89-94

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::571b171a8ab7615aa7ddb407e5c50ccc
https://doi.org/10.1097/mog.0000000000000911

Zobrazit plný text záznamu

Table S5 from A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation–Positive Solid Tumors

Autor: James A. Whitlock, Mark W. Russo, Steven Green, Noelia Nebot, Lillian Tseng, Andrew D.J. Pearson, Christine A. Pratilas, Eric Bouffet, Violet Shen, Trent R. Hummel, Kenneth J. Cohen, Anne-Isabelle Bertozzi, Isabelle Aerts, Pooja Hingorani, Darren Hargrave, Alberto Broniscer, Ira J. Dunkel, Birgit Geoerger, Mark W. Kieran

Adverse events, suspected to be study drug related, reported by primary system organ class

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::516d7fe5426956d961efcda02b459911
https://doi.org/10.1158/1078-0432.22472555

Zobrazit plný text záznamu

Data from A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation–Positive Solid Tumors

Purpose:The 2-part, phase I/IIa, open-label study (NCT01677741) sought to determine the safety, tolerability, pharmacokinetics, and preliminary activity of dabrafenib in pediatric patients with advanced BRAF V600–mutated cancers.Patients and Method

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02fd5f95aec3525ee84d5557f83cca23
https://doi.org/10.1158/1078-0432.c.6528263.v1

Zobrazit plný text záznamu

Data from Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation–Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study

Autor: Mark W. Kieran, James A. Whitlock, Eduard Gasal, Kohinoor Dasgupta, Lillian Tseng, Mark W. Russo, Ira J. Dunkel, Pooja Hingorani, Birgit Geoerger, Jordan R. Hansford, Kenneth J. Cohen, Alberto Broniscer, Uri Tabori, Eric Bouffet, Darren R. Hargrave

Purpose:Pediatric low-grade glioma (pLGG) is the most prevalent childhood brain tumor. Patients with BRAF V600 mutation–positive pLGG may benefit from treatment with dabrafenib. Part 2 of a phase I/IIa study, open-label study (NCT01677741) explores

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0e2f8fa1280651ff2814f5fa7564aa5
https://doi.org/10.1158/1078-0432.c.6529233

Zobrazit plný text záznamu

Figure S2 from Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation–Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study

Investigator-assessed percent change at maximum reduction from baseline in tumor measurement per RANO criteria

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::006db3819fbf55943d79bcc53f8717b2
https://doi.org/10.1158/1078-0432.22475958.v1

Zobrazit plný text záznamu

Figure S1 from A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation–Positive Solid Tumors

Study design

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf78d03a6bad84126201afc9b3e03751
https://doi.org/10.1158/1078-0432.22472570.v1

Zobrazit plný text záznamu

Pros and Cons of the Safety Net Rule for Prioritization of Liver Transplant Recipients Who Receive Liver Alone Transplant but Develop End-Stage Renal Disease

Autor: Mark W, Russo, Vincent, Casingal

Publikováno v: Clinics in Liver Disease. 26:269-281

The number of patients presenting with cirrhosis with kidney injury and the potential need for SLKT is increasing. In 2017, standardized criteria were implemented to identify candidates for SLKT as well as criteria for prioritizing LTA recipients for

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b210d6b919c3952eba021c26fb986ca6
https://doi.org/10.1016/j.cld.2022.01.005

Zobrazit plný text záznamu

Impact of the Corona Virus Disease 2019 Pandemic on Hepatology Practice and Provider Burnout

Autor: Norah A. Terrault, Rajender Reddy, Bilal Hameed, Elizabeth Goacher, John Lingerfelt, Nneka N. Ufere, Ryan Kwok, Jaime Chu, Mark W Russo, Serper Marina

Publikováno v: Hepatology Communications. 6:1236-1247

Background The COVID-19 pandemic has had a wide-ranging impact on the clinical practice of medicine and emotional well-being of providers. Aim To determine the impact of the COVID-19 pandemic on practice and burnout among hepatology providers. Method

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::74ffa3f97b86e133e582b1551f2eb47f
https://doi.org/10.1002/hep4.1870

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání